Plasma Filtration on Mediators of Thrombotic Microangiopathy: An in Vitro Study

Abstract

Objectives.

Sepsis-induced thrombotic microangiopathy is successfully treated by plasma exchange therapy However, certain putative mediators of thrombotic microangiopathy may not be removed by plasma filtration.

Methods.

We conducted an in vitro study to determine whether plasma filtration can remove ultra-large von Willebrand factor (ULvWF) multimers and other mediators. In separate experiments, human umbilical venous endothelial cell (HUVEC) supernatant enriched with ULvWF or human whole blood was passed through a therapeutic plasma exchange (TPE 2000, PRISMA) filter and samples were taken for measurement of ULvWF, vWF ristocetin cofactor, vWF antigen and PAI-1.

Results.

The sieving coefficients for vWF and PAI-1 were above 0.9. The ULvWF was gradually eliminated, and nearly disappeared after four circulations.

Conclusion.

The TPE 2000 filter can directly remove potential mediators of sepsis-induced thrombotic microangiopathy.

Keywords

Plasma filtration Sepsis Thrombotic microangiopathy von Willebrand factor Plasminogen activator inhibitor

Get full access to this article

View all access options for this article.

References

Kwan

H.C.

, Soff

G.A.

Seminar in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Semin Hematol 1997; 34: 1–164.

Nguyen

, Hall

, Han

, Fiedor

, Hasset

, Lopez-Plaza

. Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target? Pediatr Crit Care Med 2001; 2: 187–96.

Aird

W.C.

Sepsis and coagulation.

Crit Care Clin 2005; 21: 417–31.

Zeerleder

, Schroeder

, Hack

C.E.

, Kohler

H.P.

, Wuillemin

W.A.

TAFI and PAI-1 levels in human sepsis.

Thromb Res 2006; 118: 205–12.

Pimanda

, Hogg

Control of von Willebrand factor multimer size and implications for disease.

Blood Rev 2002; 16: 185–92.

Rock

G.A.

, Shumak

K.H.

, Buskard

N.A.

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.

N Engl J Med 1991; 325: 393–7.

Bell

W.R.

, Braine

H.G.

, Ness

P.M.

Improved survival in thrombotic thrombocytopenic purpura- hemolytic uremic syndrome.

N Engl J Med 1991; 325: 398–403.

Stegmay

B.G.

: Plasmapheresis in severe sepsis or septic shock. Blood Purif 1996; 14: 94–101.

Stegmayr

B.G.

Plasma exchange in patients with septic shock including renal failure.

Blood Purif 1996; 14: 102–8.

10.

Nguyen

T.C.

, Stegmayr

, Busund

, Bunchman

T.E.

, Carcillo

J.A.

Plasma therapies in thrombotic syndromes.

Int J Artif Organs 2005; 28: 459–65.

11.

Nguyen

T.C.

, Liu

, Ball

, Choi

, May

W.S.

, Aboulfatova

, Bergeron

A.L.

, Dong

J.F.

Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis.

Haematologica 2007; 92: 121–4.

12.

Dong

J.F.

Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions.

J Thromb Haemost 2005; 3: 1710–6.

13.

Tan

H.K.

, Hart

Plasma filtration.

Ann Acad Med Singapore 2005; 34: 615–24.

14.

Nolasco

L.H.

, Turner

N.A.

, Bernardo

, Tao

, Cleary

T.G.

, Dong

J.F.

, Moake

J.L.

Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.

Blood 2005; 15: 106: 4199–209.

15.

Nguyen

T.C.

, Carcillo

J.A.

Bench-to-bedside review: Thrombocytopenia-associated multiple organ failure - a newly appreciated syndrome in the critically ill.

Crit Care 2006; 10: 235–43.

16.

Lawlor

E.R.

, Webb

D.W.M.

, Hill

Thrombotic thrombocytopenic purpura: A treatable cause of childhood encephalopathy.

J Pediatr 1997; 30: 313–6.